Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders
Authors:
- Violeta MolagicVMVioleta Molagic
- Raluca MihailescuRMRaluca Mihailescu
- Catalin TiliscanCTCatalin Tiliscan
- Cristina PopescuCPCristina Popescu
- Ana Maria VladareanuAVAna Maria Vladareanu
- Remulus CatanaRCRemulus Catana
- Mihaela RadulescuMRMihaela Radulescu
- Victoria AramaVAVictoria Arama
- Stefan Sorin AramaSAStefan Sorin Arama
- 18 January 2019
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 35 (3) , 459-464
Abstract
Hepatitis B and C virus (HBV and HCV) reactivations have become more common following the intensive use of biological therapies for the treatment of chronic lymphoproliferative disorders (CLD). We evaluate risk factors for virus reactivation and exitus in patients diagnosed with CLD and HBV or HCV infection, undergoing rituximab-chemotherapy (R-chemo). A prospective, observational study in two tertiary-care Romanian hospitals, between December 2007 and May 2010, of patients diagnosed with CLD undergoing R-chemo. HBV and HCV serological markers, viral load, fibrosis and necroinflammation were assessed at baseline and every 3–6 months. We screened 502 patients diagnosed with CLDs (77.2% non-Hodgkin lymphomas) and enrolled 57 patients with HBV and/or HCV infection with a mean age of 61.35 ± 11.1 years. The replicative virus was HBV in 23 patients (40.3%), HCV in 33 patients (57.9%). HCV reactivation rate (15.6%) was lower than for HBV (45.5%) (p = 0.02). In univariate analysis, viral reactivation was associated with aggressive CLD (p = 0.01), HBV (p = 0.01) and lymphopenia (p = 0.02). Death was associated with aggressive CLD (p = 0.01), viral reactivation (p = 0.001) and high baseline viremia (p = 0.05). In multivariate analysis, viral reactivation was associated with lymphopenia (OR 0.05, 95% CI 0.003–0.85, p = 0.03). Risk of death was 10 times higher for patients with viral reactivation (95% CI 1.54–65.5, p = 0.01). A quarter of the infected patients were diagnosed with viral reactivation. While hepatitis C was more prevalent than hepatitis B in patients with CLD, viral reactivation was found 3 times more frequently in patients with hepatitis B than C.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort StudyIndian Journal of Hematology and Blood Transfusion, 2012
- Reactivation of hepatitis B virus and hepatitis C virus in patients with cancerNature Reviews Clinical Oncology, 2012
- Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapyScandinavian Journal of Infectious Diseases, 2011
- Prevalence of hepatitis B virus infection in non‐Hodgkin lymphoma: a systematic review and meta‐analysisInternal Medicine Journal, 2010
- Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic StudiesCancer Epidemiology, Biomarkers & Prevention, 2006
- Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic ChemotherapyGastroenterology, 2006
- Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapyHepatology, 2006
- Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCCHepatology Research, 2003
- Steroid–Free Chemotherapy Decreases Risk of Hepatitis B Virus (Hbv) Reactivation in Hbv–Carriers With LymphomaHepatology, 2003
- Association of a precore genomic variant of hepatitis B virus with fulminant hepatitisHepatology, 1991